Furthermore, in commercial HN5 and FaDu cells, as well as 20 different HNSCC patient-derived cell lines, a combination of cetuximab and vismodegib (inhibitor of the Hh pathway) confirmed the benefits of EGFR and Hh co-inhibition [120]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.